Electron microscopy

Electron microscopy and immunoelectron microscopy were performed as described. For electron microscopy, cell samples were fixed in 1.5% glutaraldehyde for 2 h. For immunoelectron microscopy, cells were fixed with 0.1% glutaraldehyde for 10 min.

Reverse transcription-polymerase chain reaction (RT-PCR)

After four days culture of Flk1+ cells with 10% FCS, cells (Fig. 1b) were used as a source of SMA* RNA. Total RNA was prepared with Trizol reagent (Life Technologies, Inc.), reverse transcribed by oligo (dT) priming and PowerScript-Reverse Transcriptase (CLONTECH Laboratories), and PCR was performed with the following primers: SMA forward: 5′-AC GGGCCCTCTCTCTGC-3′, reverse: 5′-GGCAGGTCCCTGCATTC-3′, smooth muscle myosin heavy chain forward: 5′-GACAACCTCTCTGTTTGG-3′, reverse: 5′-GCTCCTCAAAAGCAGGTAC-3′, h1-calponin forward: 5′-GATGAGATTAGGAGGGTACAGAGGC-3′, reverse: 5′-GATAACAGGTATCCACCTCTTCAGC-3′, SM22a forward: 5′-GAGCTCCCAATTGAGAAGA-3′, reverse: 5′-CTTGGTCTGGCCATTTAGAAG-3′.

Chick/mouse chimaeric assay

CCE/nLacZ cells were generated by cotransfection of elongation factor 1 promoter-driven LacZ gene with nuclear localization signal (T. Kuniyasu) and murine phospholipase C kinase 1 promoter-driven puromycin resistant gene constructs and selection by 2 μg/ml puromycin. We injected 1–2 × 106 Flk1+ cells in 2–4 μl of phosphate buffered saline (PBS) into hearts of stage 16–18 chick embryos with glass needles. Embryos were killed 2–3 days after injection and fixed with 2% paraformaldehyde at 4°C for 10 min. A X-gal analogue, magenta gal (Nakarai), was used as substrate for whole-mount staining: stained embryos were frozen in OCT, cryosectioned at 6–7 μm and stained for PECAM1 or SMA. PECAM1 staining was performed using TSA Indirect, tyramide signal amplification reagent (NEN Life Science Products).

Received 26 June; accepted 23 August 2000.

Acknowledgements

We thank M. J. Evans for CCE ES cells, N. Matsuysu for the hybridoma, A. Nagafuchi for antibodies, T. Kuniyasu for LacZ construct, R. Yu for critical reading of the manuscript, and many of our colleagues for suggestions and discussion. This work was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan, the Ministry of Health and Welfare of Japan (S.L.N.), Japanese Society for the Promotion of Science "Research for the Future" Program (H.L., M.O. and S.I.N.), Japan Tobacco Foundation, Japan Heart Found & Pfizer Pharmaceuticals Grant for Research on Coronary Artery Disease and Tanabe Medical Frontier Conference. J.Y. is a recipient of the Research Fellowship grant of the Japan Society for the Promotion of Science for Young Scientists. Correspondence and requests for materials should be addressed to J.Y. (e-mail: juny@kuhp.kyoto-u.ac.jp).

Bidirectional control of airway responsiveness by endogenous cannabinoids

A. Calligano*, I. KátOna†, F. Désarnaud†, A. Giuffrida†, G. La Rana*, K. Mackie†, T. F. Freund‡ & D. Piomelli‡

* Department of Pharmacology, University of Naples, Naples 80131, Italy
† Institute of Experimental Medicine, Budapest 1450, Hungary
‡ Department of Pharmacology, University of California, Irvine, California 92697-4625, USA
§ Department of Anesthesiology, University of Washington, Seattle, Washington 98195-6540, USA

Smoking marijuana or administration of its main active constituent, Δ9-tetrahydrocannabinol (Δ9-THC), may exert potent dilating effects on human airways1-4. But the physiological significance of this observation and its potential therapeutic value are obscured by the fact that some asthmatic patients respond to these compounds with a paradoxical bronchospasm5,6. The mechanisms underlying these contrasting responses remain unresolved. Here we show that the endogenous cannabinoid anandamide exerts dual effects on bronchial responsiveness in rodents: it strongly inhibits bronchospasm and cough evoked by the chemical irritant, capsaicin, but causes bronchospasm when the constricting tone exerted by the vagus nerve is removed. Both effects are mediated through peripheral CB1 cannabinoid receptors found on axon terminals of airway nerves. Biochemical
analyses indicate that anandamide is synthesized in lung tissue on calcium-ion stimulation, suggesting that locally generated anandamide participates in the intrinsic control of airway responsiveness. In support of this conclusion, the CB1 antagonist SR141716A enhanced capsaicin-evoked bronchospasm and cough. Our results may account for the contrasting bronchial actions of cannabis-like drugs in humans, and provide a framework for the development of more selective cannabinoid-based agents for the treatment of respiratory pathologies.

To explore the functional roles of the cannabinoid system in airway physiology, we investigated the effects of the endogenous cannabinoid, anandamide, on the responsiveness of bronchial smooth muscle. Administration of capsaicin, the pungent component of chilli pepper, produces a potent bronchoconstriction in anaesthetized guinea pigs (Fig. 1a) or rats (in μg per animal, intratracheal: 10, 41 ± 6% of maximal bronchospasm; 30, 55 ± 12%; 100, 81 ± 19; means ± s.e.m., n = 3). This response, which has been extensively studied both in animals and humans, is thought to result from the activation of capsaicin (or ‘vanilloid’) receptors on sensory C-fibres. Accordingly, the constricting effects of capsaicin were blocked by the vanilloid antagonist capsazepine (Caps, 0.2 mg per kg i.v.). After vagotomy and atropine administration, which eliminate vagal influences, systemic application of anandamide (AEAs, mg per kg i.v.) (0.5 mg per kg i.v.) on guinea pig bronchial smooth muscle and its antagonism by capsapine (Caps, 0.2 mg per kg i.v.).

Figure 1 Anandamide inhibits bronchospasm and coughing in guinea-pigs by activating peripheral CB1 receptors. a, Constricting effect of capsaicin (Caps, μg per kg i.v.) on guinea pig bronchial smooth muscle and its antagonism by capsazepine (Cpz, 0.2 mg per kg i.v.) on guinea-pigs (Fig. 1b) and rats (capsaicin, 10 μg per kg i.v.) on capsaicin-evoked bronchospasm in the absence or presence of SR141716A (SR1, 0.5 mg per kg i.v.) or the CB2 antagonist SR144528 (SR2, 0.3 mg per kg i.v.). b, Inhibitory effects of anandamide (AEA, mg per kg i.v.) on capsaicin-evoked bronchospasm in the absence or presence of the CB1 antagonist SR141716A (SR1, 0.5 mg per kg i.v.) or the CB2 antagonist SR144528 (SR2, 0.3 mg per kg i.v.). Similar effects were observed when anandamide was injected into the guinea-pig bronchi through a tracheal catheter (Fig. 2b), or applied to isolated strips of guinea-pig lung parenchyma (Fig. 2c–e). The slow onset of the anandamide response in strips of guinea-pig lung is consistent with results obtained in other isolated tissues; the low potency of anandamide in this preparation may be accounted for by limited tissue penetration and/or rapid inactivation. In agreement with this possibility, the anandamide transport inhibitor AM404 enhanced anandamide-evoked contractions in isolated strips of guinea-pig lung (anandamide, 50 μM, 0.336 ± 0.07 dyne mg⁻¹ of tissue, n = 3); anandamide plus AM404, 28 μM, 0.638 ± 0.06 dyne mg⁻¹ of tissue; P < 0.05, n = 6). The CB1 antagonist SR141716A blocked anandamide-induced bronchoconstriction in vagotomized, atropine-treated guinea pigs by activating peripheral CB1 receptors. a, Effects of anandamide (AEA, mg per kg i.v.) in the presence or absence of the CB1 antagonist SR141716A (SR1, 0.2 mg per kg i.v.) (n = 6 for each condition). b, Effects of anandamide (5–30 μg per kg i.v.) or AM404 (0.2 mg per kg i.v.) in the presence or absence of the CB1 antagonist SR141716A (SR1, 0.3 mg per kg i.v.) (n = 6). c, Representative tracing illustrating the effect of anandamide (100 μM) on muscle tension in guinea pig parenchyma strips and its reversal by the CB1 antagonist SR141716A (1 μM). d, Response of the same lung strip to histamine (His, 10 μM), 0.2 mg per kg i.v. (n = 6 for each condition). e, Responses of lung parenchyma by anandamide (μM) and antagonism by SR141716A (1 μM) (n = 6). Asterisk, *P < 0.01.
anandamide bronchoconstriction in vivo and in vitro (Fig. 2a–e), whereas the CB2 antagonist SR144528 had no effect (data not shown). The cannabinoid agonist HU210 was also potent at eliciting guinea pig bronchial muscle constriction after tracheal administration (in μg per animal: 10.0 ± 0.6% of maximal bronchospasm; 1, 30 ± 1.2%; 10, 60 ± 2.2%; 30, 100%; n = 6). Anandamide has been claimed to activate vanilloid receptors 15. However, the vanilloid antagonist capsazepine had no effect on anandamide-evoked bronchospasm at a dose that completely prevented the capsaicin response (0.2 mg per kg i.v.) (data not shown). These results indicate that removing the vagal excitatory tone unmasked a bronchoconstricting activity of anandamide mediated through CB1 receptors.

The ability of anandamide to influence bronchial muscle contractility after local administration suggests that this compound may exert its effects by activating CB1 receptors located within the airways. To test this possibility, we examined the ultrastructural localization of CB1 receptors in rat lungs by electron microscopy, using an antibody directed against the intracellular carboxy terminus of the CB1 receptor protein. Immunogold staining revealed that CB1 receptors are present on nerve fibres distributed among bronchial and bronchiolar smooth muscle cells (Fig. 3a–c), or between the longitudinal and circular smooth muscle layers, wherever several axons are packed together into glial capsules (Fig. 3d, e). All bundles contained at least one CB1-receptor-positive axon. Detailed evaluation (20 bundles consisting of 91 axons followed through at least 25 consecutive sections) revealed that 36% of the axons were labelled with the CB1 receptor antibody. The gold particles that labelled CB1 receptors were attached to the inner surface of the axon plasma membrane, either at the release site or in the preterminal segments. This is consistent with the fact that the antibody we used recognizes the intracellular C terminus of the CB1 receptor protein. Axon terminals bearing CB1 receptor immunoreactivity were in close proximity to smooth muscle cells (0.2–0.5 μm), and contained a large number of small agranular vesicles, along with few dense-core vesicles (Fig. 3a, b). In some cases, CB1 receptor immunoreactivity was adjacent to clusters of vesicles accumulated at the plasma membrane, which most probably represent neurotransmitter release sites (Fig. 3c).

Next, to determine whether CB1 receptors are localized on noradrenaline-containing and/or non-noradrenaline-containing fibres, we used a combination of immunogold staining for CB1 receptors, and immunoperoxidase staining for neuropeptide Y (NPY), a co-transmitter in sympathetic neurons9. We found that 63% of NPY-bearing axons were also CB1-receptor-positive (Fig. 3f, g). Notably, however, extensive labelling was observed on many NPY-negative axons (data not shown), suggesting that both noradrenaline-containing and/or non-noradrenaline-containing nerves may express CB1 receptors.

The finding that CB1 receptors are found predominantly, if not
exclusively, on axon terminals of airway nerves indicates that anandamide may regulate bronchial smooth muscle tone through a prejunctional mechanism. Inhibition of excitatory neurotransmission in the airways may provide a parsimonious explanation for the ability of anandamide to oppose capsaicin-evoked bronchospasm and cough. This interpretation is further supported by the ability of anandamide and other cannabinoid agonists to inhibit neurotransmitter release in both peripheral tissues and the central nervous system. The mechanism underlying the constriction actions of anandamide in animals lacking acetylcholine-mediated control is currently unknown. One possibility, which is consistent with the co-localization of CB1 receptors with NPY, is that anandamide inhibits the release of a bronchodilating mediator. Alternatively, anandamide may interact with CB1 receptors on smooth muscle. Our failure to detect CB1 receptor immunoreactivity in lung smooth muscle may have been caused by insufficient sensitivity of our technique, or by the presence in smooth muscle of a receptor variant that is not recognized by our antibody. Interestingly, northern blot analyses suggest that alveolar type II cells in the lung tissue may express two different CB1 receptor messenger RNA species.

To test the possibility that endogenous cannabinoids regulate airway responsiveness, we determined the intrinsic effects of CB1 and CB2 antagonists on bronchospasm and cough in guinea-pigs. CB1 receptor blockade with SR141716A had no bronchomotor consequences per se, but significantly enhanced the bronchoconstriction and coughing evoked by capsaicin administered through a tracheal catheter (Fig. 4a, b), even in the presence of anandamide (Fig. 1b, c). This response did not depend on the capsaicin administration route, as it was also seen after i.v. injection of the drug (30 mg per kg capsaicin alone, 55.3 ± 8.2% of maximal bronchospasm; capsaicin after SR141716 (0.5 mg per kg i.v.), 92.3 ± 3.4%; P < 0.05, n = 3). The CB2 antagonist SR144528 had no effect on capsaicin-induced bronchoconstriction and cough (data not shown).

Although the bronchomotor actions of the CB1 antagonist may be accounted for by its inverse agonist properties, evidence suggests that this drug acts by opposing an ongoing cannabinoid modulation. First, the lack of effect seen with the CB1 antagonist in the absence of capsaicin is incompatible with an inverse agonist behaviour. Second, analyses by high-performance liquid chromatography (HPLC) coupled to positive-ionization electrospray mass spectrometry (MS) revealed that anandamide is synthesized in rat lung tissue through a Ca2+-ion-activated mechanism (Fig. 5). Rat lung membranes produced on average 0.6 ± 0.2 pmol of anandamide per mg of protein in the presence of the Ca2+ chelator EGTA (1 mM); and 1.6 ± 0.2 pmol of anandamide per mg of protein in the presence of Ca2+ (3 mM) (mean ± s.e.m., n = 4; P < 0.05 between EGTA and Ca2+; Student’s t-test) (Fig. 5, inset). Guinea-pig lung membranes produced 0.9 ± 0.3 pmol of anandamide per mg of protein in the presence of EGTA; and 8.8 ± 1.2 pmol of anandamide per mg of protein in the presence of Ca2+ (n = 4; P < 0.0001; Student’s t-test).

Anandamide is thought to originate from the enzymatic cleavage of N-arachidonyl phosphatidylethanolamine (NAPE), the biosynthesis of which is catalysed by a Ca2+-dependent N-acyltransferase activity. Using negative ionization electrospray HPLC/MS, we identified two molecular species of NAPE in lipid extracts of rat lung membranes: alk-1-palmitoyle-2-arachidonyl-sn-glycero-phosphoethanolamine-N-arachidonoyl (NAPE 1; Fig. 6a) and alk-1-stearyl-2-arachidonyl-sn-glycero-phosphoethanolamine-N-arachidonoyl (NAPE 2; Fig. 6a). Identifications were based (1) on the occurrence of deprotonated molecules of appropriate mass (NAPE 1: mass-to-charge ratio (m/z) 370); and NAPE 2, m/z 374, [M + Na]+), which was added to the samples as an internal standard. The inset in a illustrates the effects of EGTA (1 mM) or Ca2+ (3 mM) on anandamide biosynthesis in rat lung membranes. Ca2+ significantly stimulated anandamide formation (mean ± s.e.m.; asterisk, P < 0.05, n = 4).

Letters to Nature
This page discusses the biological and pharmacological effects of cannabinoids, specifically anandamide. It explains how anandamide, an endogenous cannabinoid, may contribute to bronchomotor actions and bronchoconstriction. The text also mentions the role of the bronchial muscle state in the release of anandamide and its potential role in the development of new antitussive and anti-asthmatic agents.

**Methods**

**Chemicals**

Anandamide and [3H]anandamide were synthesized following standard procedures; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine-N-arachidonyl and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-oleyl were purchased from Avanti Polar Lipids (Alabaster, AL); SR144528 (N-((4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) was provided by RBI (Natick, MA) as part of the Chemical Synthesis Program of the NIMH (N01MH30003); all other drugs were from Tocris (Ballwin, MO) or Sigma (Saint Louis, MO).

**Biological assays**

For bronchospasm, we anesthetized Dunkin-Hartley guinea-pigs (Charles-River, weighing 200–400 g) or Wistar rats (Charles-River, weighing 200–300 g) with pentobarbital (40 mg per kg intraperitoneal (i.p.)) and fentanyl (25 μg per kg intramuscularly), catheterized the trachea and carotid artery to measure airway obstruction and systemic blood pressure, and catheterized the jugular vein to administer drugs. Pencuronium bromide (4 mg per kg i.v.) was administered to prevent spontaneous breathing. The animals were ventilated with room air using a rodent ventilator (U. Basile, Comerio, Italy) run at 60 strokes min⁻¹; stroke volume was 3–7 ml. Airway resistance was measured by using a differential pressure transducer (U. Basile) connected by the side-arm of the tracheal catheter to a bronchospasm transducer. Broncospasm was expressed as a percent of the maximal response, which was determined by clamping the tracheal catheter before and after each experiment. Drugs were dissolved in saline containing 10% DMSO, and injected through the jugular vein; responses were evaluated at their peak. Arterial blood pressure was measured continuously with a pressure transducer connected to a recorder (U. Basile). To abolish vagal influences on bronchial musculature, in some experiments we bilaterally transected the vagus nerves and administered atropine sulphate (2 mg per kg i.v.). Anandamide was administered 15 min before capsaicin; the antagonists were given 15 min before anandamide.

**Electron microscopy**

The lungs were removed from three rats perfused with a phosphate-buffered (0.1 M) fixative containing 4% paraformaldehyde, 0.2% picric acid and 0.05% glutaraldehyde, and were fixed at 37°C in Tris buffer (50 mM, pH 7.4) containing CaCl₂ (3 mM) or EGTA (1 mM) and after each experiment. Drugs were dissolved in saline containing 10% DMSO, and injected through the jugular vein; responses were evaluated at their peak. Arterial blood pressure was measured continuously with a pressure transducer connected to a recorder (U. Basile). To abolish vagal influences on bronchial musculature, in some experiments we bilaterally transected the vagus nerves and administered atropine sulphate (2 mg per kg i.v.). Anandamide was administered 15 min before capsaicin; the antagonists were given 15 min before anandamide.

**HPLC/MS**

Anandamide was identified and quantified by reversed-phase HPLC coupled to positive ionization electrospray MS, using an isotope-dilution method as described. We purified NPY antibodies by reversed-phase HPLC on a C₁₈ (300 × 3.9 mm internal diameter 5 μm) column maintained at 20°C and interfaced with an Agilent HP1100 model mass spectrometer. HPLC conditions consisted of a linear gradient of methanol in water (from 75% to 100% methanol in 30 min) with a flow rate of 1 ml min⁻¹. Under these conditions, different NPY species were eluted from the column as a group of peaks at retention times comprising 27–29 min. MS analyses were performed with the electrospray ion source set in the negative ionization mode; the V_cap set at 5 kV; and the fragmentor voltage set at 200 V. Nitrogen was used as a drying gas at a flow rate of

---

**Figure 6** Ca²⁺-dependent biosynthesis of anandamide precursors in rat lung.

- **a.** Structures of alk-1-palmitoyl-2-ara-chidonyl-sn-glycero-phosphoethanolamine-N-arachidonyl (top panel, NAPE 1) and alk-1-stearoyl-2-arachidonyl-sn-glycero-phosphoethanolamine-N-arachidonyl (bottom panel, NAPE 2), two anandamide precursors.
- **b.** Representative HPLC/MS tracings for selected ions characteristic of NAPE 1 (top panel), m/z = 1009, deprotonated molecule, [M – H]⁻, and NAPE 2 (bottom panel), m/z = 1039, [M – H]⁻. The insets show that biosynthesis of NAPE 1 (top panel) and NAPE 2 (bottom panel) was significantly stimulated by Ca²⁺ (3 mM) (mean ± s.e.m.; asterisk, P < 0.05, n = 4).
A growing number of human neurodegenerative diseases result from the expansion of a glutamine repeat in the protein that causes the disease. Spinocerebellar ataxia type 1 (SCA1) is one such disease—caused by expansion of a polyglutamine tract in the protein ataxin-1. To elucidate the genetic pathways and molecular mechanisms underlying neuronal degeneration in this group of diseases, we have created a model system for SCA1 by expressing the full-length human SCA1 gene in Drosophila. Here we show that high levels of wild-type ataxin-1 can cause degenerative phenotypes similar to those caused by the expanded protein. We conducted genetic screens to identify genes that modify SCA1-induced neurodegeneration. Several modifiers highlight the role of protein folding and protein clearance in the development of SCA1. Furthermore, new mechanisms of polyglutamine pathogenesis were revealed by the discovery of modifiers that are involved in RNA processing, transcriptional regulation and cellular detoxification. These findings may be relevant to the treatment of polyglutamine diseases and, perhaps, to other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.

Drosophila provides a flexible and powerful model to study neurodegenerative diseases. Using the GAL4/UAS system, we can control the level of transgene expression and direct expression to different cell types or even to specific neurons. Large-scale genetic screens allow us to identify the genes and pathways involved in pathogenesis. Because most of the genetic pathways involved in normal development and disease conditions are conserved between Drosophila and mammals, mechanisms of neuronal degeneration in Drosophila may prove relevant to neurodegeneration in humans. Drosophila models using polyglutamine or truncated polypeptides of ataxin-3 and huntingtin, for example, show the characteristic progressive neural degeneration and pathology3,6, and overproduction of the Hsp70 and Hsp40 molecular chaperones suppresses polyglutamine-induced neurotoxicity5,3.

Because polyglutamine peptides tend to be more toxic than the full-length proteins and do not elicit the cell-type-specific neurodegeneration characteristic of these diseases3, their activities might be distinct from those of the full-length proteins. Therefore, we generated transgenic flies expressing full-length ataxin-1 using the GAL4/UAS system. We cloned two human SCA1 complementary DNAs, differing in the size of their polyglutamine repeat tracts, into the Drosophila transformation vector pUAST. These constructs encoded ataxin-1 30Q (a wild-type human isoform) and ataxin-1 82Q (an expanded isoform) (Fig. 1). Six 82Q and four 30Q lines were generated.

We directed SCA1 expression to the eye retina using the gmr-GAL4 driver and estimated ataxin-1 levels in all transgenic lines by